MedTrace Logo

Peak Plasma Levels of Bupivacaine After an Erector Spinae Block (ESP)

NCT03841409 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2022-05-31

No results posted yet for this study

Summary

The primary objective of the study is to measure plasma levels of bupivacaine following erector spinae (ESP) regional block in patients undergoing mastectomy.

Conditions

  • Pharmacokinetics
  • Anesthesia, Local

Interventions

OTHER

Collection of blood samples

Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.

Sponsors & Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • Stephan Williams, MD, PhD · Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-14
Primary Completion
2019-10-16
Completion
2019-10-16

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03841409 on ClinicalTrials.gov